Compare Stocks: BOLD, LRMR, LXEO, and CAMP

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLD Boundless Bio	$2.34 -0.4%	$2.74	$0.96 ▼ $3.16	$53.46M	0.02	189,124 shs	711,179 shs
CAMP CAMP4 Therapeutics	$3.17 -8.1%	$4.12	$2.86 ▼ $7.75	$216.50M	0.27	328,250 shs	92,405 shs
LRMR Larimar Therapeutics	$1.99 -0.3%	$3.57	$1.92 ▼ $6.42	$206.73M	0.68	1.73 million shs	1.69 million shs
LXEO Lexeo Therapeutics	$2.64 -4.3%	$4.15	$2.56 ▼ $10.99	$226.45M	1.63	2.07 million shs	2.51 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLD Boundless Bio	-0.43%	-7.51%	-17.02%	-5.65%	+76.20%
CAMP CAMP4 Therapeutics	-8.12%	-15.92%	-17.88%	-14.56%	-8.46%
LRMR Larimar Therapeutics	-0.25%	-25.66%	-49.49%	-46.35%	-53.18%
LXEO Lexeo Therapeutics	-4.35%	-18.27%	-36.54%	-43.71%	-70.10%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BOLD Boundless Bio	$2.34 -0.4%	$2.74	$0.96 ▼ $3.16	$53.46M	0.02	189,124 shs	711,179 shs
CAMP CAMP4 Therapeutics	$3.17 -8.1%	$4.12	$2.86 ▼ $7.75	$216.50M	0.27	328,250 shs	92,405 shs
LRMR Larimar Therapeutics	$1.99 -0.3%	$3.57	$1.92 ▼ $6.42	$206.73M	0.68	1.73 million shs	1.69 million shs
LXEO Lexeo Therapeutics	$2.64 -4.3%	$4.15	$2.56 ▼ $10.99	$226.45M	1.63	2.07 million shs	2.51 million shs

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BOLD Boundless Bio	-0.43%	-7.51%	-17.02%	-5.65%	+76.20%
CAMP CAMP4 Therapeutics	-8.12%	-15.92%	-17.88%	-14.56%	-8.46%
LRMR Larimar Therapeutics	-0.25%	-25.66%	-49.49%	-46.35%	-53.18%
LXEO Lexeo Therapeutics	-4.35%	-18.27%	-36.54%	-43.71%	-70.10%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BOLD Boundless Bio	1.00	Sell	N/A	N/A
CAMP CAMP4 Therapeutics	2.70	Moderate Buy	$10.50	231.23% Upside
LRMR Larimar Therapeutics	3.00	Buy	$10.33	420.57% Upside
LXEO Lexeo Therapeutics	3.00	Buy	$16.43	522.29% Upside

Current Analyst Ratings Breakdown

Latest BOLD, LRMR, LXEO, and CAMP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/15/2026	LRMR Larimar Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Sell (D-)
10/15/2026	CAMP CAMP4 Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Neutral ➝ Buy	$8.00
10/5/2026	CAMP CAMP4 Therapeutics	Oppenheimer Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$15.00
10/2/2026	CAMP CAMP4 Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)
9/29/2026	CAMP CAMP4 Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Overweight
9/29/2026	CAMP CAMP4 Therapeutics	Chardan Capital Subscribe to MarketBeat All Access to unlock brokerage rankings	Lower Price Target	Buy	$6.50 ➝ $6.00
9/23/2026	LXEO Lexeo Therapeutics	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Outperform	$15.00
9/22/2026	LXEO Lexeo Therapeutics	Raymond James Financial Subscribe to MarketBeat All Access to unlock brokerage rankings	Reiterated Rating	Strong-Buy
9/17/2026	CAMP CAMP4 Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Upgrade	Sell (E+) ➝ Sell (D-)
9/14/2026	LRMR Larimar Therapeutics	Leerink Partners Subscribe to MarketBeat All Access to unlock brokerage rankings	Initiated Coverage	Outperform	$13.00
9/2/2026	CAMP CAMP4 Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access to unlock brokerage rankings	Downgrade	Sell (D-) ➝ Sell (E+)

(Data available from 10/17/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BOLD Boundless Bio	N/A	N/A	N/A	N/A	$4.41 per share	N/A
CAMP CAMP4 Therapeutics	$3.50M	56.83	N/A	N/A	$1.02 per share	3.11
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	$0.94 per share	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	$3.38 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BOLD Boundless Bio	-$58.20M	-$2.86	N/A	N/A	N/A	N/A	-70.89%	-47.37%	N/A
CAMP CAMP4 Therapeutics	-$80.40M	-$2.32	N/A	N/A	N/A	-2,543.74%	-252.79%	-85.65%	N/A
LRMR Larimar Therapeutics	-$165.67M	-$1.95	N/A	N/A	N/A	N/A	-137.39%	-97.65%	11/5/2026 (Estimated)
LXEO Lexeo Therapeutics	-$99.96M	-$1.15	N/A	N/A	N/A	N/A	-41.85%	-38.03%	12/14/2026 (Estimated)

Latest BOLD, LRMR, LXEO, and CAMP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	LRMR Larimar Therapeutics	-$0.35	N/A	N/A	N/A	N/A	N/A
8/13/2026	Q2 2026	CAMP CAMP4 Therapeutics	-$0.24	-$0.58	-$0.34	-$0.58	N/A	$1.78 million
8/12/2026	Q2 2026	LXEO Lexeo Therapeutics	-$0.2852	-$0.30	-$0.0148	-$0.30	N/A	N/A
8/7/2026	Q2 2026	BOLD Boundless Bio	N/A	-$1.06	N/A	-$1.06	N/A	N/A
8/4/2026	Q2 2026	LRMR Larimar Therapeutics	-$0.3815	-$0.30	+$0.0815	-$0.30	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BOLD Boundless Bio	N/A	N/A	N/A	N/A	N/A
CAMP CAMP4 Therapeutics	N/A	N/A	N/A	N/A	N/A
LRMR Larimar Therapeutics	N/A	N/A	N/A	N/A	N/A
LXEO Lexeo Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BOLD Boundless Bio	N/A	9.48	9.48
CAMP CAMP4 Therapeutics	N/A	4.70	4.70
LRMR Larimar Therapeutics	N/A	4.70	4.70
LXEO Lexeo Therapeutics	N/A	13.89	13.89

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BOLD Boundless Bio	N/A
CAMP CAMP4 Therapeutics	N/A
LRMR Larimar Therapeutics	91.92%
LXEO Lexeo Therapeutics	60.67%

Insider Ownership

Company	Insider Ownership
BOLD Boundless Bio	23.10%
CAMP CAMP4 Therapeutics	21.69%
LRMR Larimar Therapeutics	4.00%
LXEO Lexeo Therapeutics	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BOLD Boundless Bio	28	22.75 million	17.49 million	No Data
CAMP CAMP4 Therapeutics	644	62.75 million	49.14 million	No Data
LRMR Larimar Therapeutics	71	103.88 million	99.73 million	Optionable
LXEO Lexeo Therapeutics	59	82.05 million	80.41 million	Not Optionable

BOLD, LRMR, LXEO, and CAMP Headlines

Recent News About These Companies

Lexeo Therapeutics to Participate in the Chardan Healthcare Conference

October 8, 2026 | globenewswire.com

Stifel Nicolaus Sticks to Its Buy Rating for Lexeo Therapeutics, Inc. (LXEO)

October 7, 2026 | theglobeandmail.com

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)

October 1, 2026 | finance.yahoo.com

Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 (MDS)

October 1, 2026 | globenewswire.com

490,331 Shares of Lexeo Therapeutics, Inc. $LXEO Purchased by Bank of America Corp DE

October 1, 2026 | marketbeat.com

【LXEO】Lexeo Therapeutics

September 29, 2026 | note.comN

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from Brokerages

September 29, 2026 | marketbeat.com

Leerink Partners Keeps Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)

September 26, 2026 | theglobeandmail.com

Lexeo to acquire Mantle Therapeutics

September 24, 2026 | thepharmaletter.comT

Leerink Partners Reaffirms "Outperform" Rating for Lexeo Therapeutics (NASDAQ:LXEO)

September 23, 2026 | marketbeat.com

Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich Ataxia

September 23, 2026 | prnewswire.com

Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic Forum

September 23, 2026 | globenewswire.com

Lexeo Therapeutics, Inc. agreed to acquire Mantle Therapeutics Inc. for $21.3 million .

September 22, 2026 | marketscreener.comM

Lexeo Therapeutics to Acquire Mantle Therapeutics for Up to $21.3 Million; Enters Three Research Collaborations

September 22, 2026 | finance.yahoo.com

Lexeo Therapeutics Signs Series Of Strategic Transactions To Expand Presence In Friedreich Ataxia

September 22, 2026 | rttnews.com

Lexeo Expands Friedreich Ataxia Pipeline Through Mantle Deal, New Collaborations

September 22, 2026 | rttnews.com

Lexeo Therapeutics, Inc. (LXEO) M&A Call Transcript

September 22, 2026 | seekingalpha.com

Lexeo Therapeutics expands FA pipeline with Mantle acquisition

September 22, 2026 | tipranks.com

Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich Ataxia

September 22, 2026 | globenewswire.com

Wall Street Zen Upgrades Lexeo Therapeutics (NASDAQ:LXEO) to Sell

September 19, 2026 | marketbeat.com

Lexeo Therapeutics to Participate in Upcoming Investor Conferences in September

September 2, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

BOLD, LRMR, LXEO, and CAMP Company Descriptions

Boundless Bio NASDAQ:BOLD

$2.34 -0.01 (-0.43%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$2.34 0.00 (0.00%)

As of 10/16/2026 04:10 PM Eastern

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

CAMP4 Therapeutics NASDAQ:CAMP

$3.17 -0.28 (-8.12%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$3.18 +0.00 (+0.16%)

As of 10/16/2026 07:30 PM Eastern

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location. The company also offers telematics products, including asset tracking units, mobile telematics devices, fixed and mobile wireless gateways, and routers; and advanced telematics products for the broader connected vehicle and Internet of Things marketplace, which enable customers to optimize their operations by collecting, monitoring, and reporting business-critical information and desired intelligence from remote and mobile assets. In addition, it offers professional services, including project management, engineering services, and installation services. The company sells its products and services to customers in the automotive, telecommunications, industrial equipment, transportation and logistics, government and municipalities, insurance, original equipment manufacturers, and leasing companies. It markets through direct sales organization, channel partner program, original equipment manufacturers, and independent sales representatives and distributors, as well as its websites and digital platform. The company was incorporated in 1981 and is headquartered in Irvine, California.

Larimar Therapeutics NASDAQ:LRMR

$1.98 -0.01 (-0.25%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$2.01 +0.02 (+1.06%)

As of 10/16/2026 07:56 PM Eastern

Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease. Larimar Therapeutics, Inc. is based in Bala Cynwyd, Pennsylvania.

Lexeo Therapeutics NASDAQ:LXEO

$2.64 -0.12 (-4.35%)

Closing price 10/16/2026 04:00 PM Eastern

Extended Trading

$2.64 -0.01 (-0.19%)

As of 10/16/2026 07:30 PM Eastern

Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BOLD, LRMR, LXEO, and CAMP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BOLD, LRMR, LXEO, and CAMP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BOLD, LRMR, LXEO, and CAMP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BOLD, LRMR, LXEO, and CAMP Company Descriptions

Boundless Bio NASDAQ:BOLD

CAMP4 Therapeutics NASDAQ:CAMP

Larimar Therapeutics NASDAQ:LRMR

Lexeo Therapeutics NASDAQ:LXEO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest BOLD, LRMR, LXEO, and CAMP Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest BOLD, LRMR, LXEO, and CAMP Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

BOLD, LRMR, LXEO, and CAMP Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

BOLD, LRMR, LXEO, and CAMP Company Descriptions

Boundless Bio NASDAQ:BOLD

CAMP4 Therapeutics NASDAQ:CAMP

Larimar Therapeutics NASDAQ:LRMR

Lexeo Therapeutics NASDAQ:LXEO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools